English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We reported two cases of angiosarcoma of the scalp (case 1: 71 years-old male, case 2: 68 years-old female) . Both patients showed recurrence of the skin after chemotherapy (carboplatin, ifosfamide, vindecine), and IL-2 therapy. Therefore we perfomed intravenous chemotherapy of docetaxel (40mg/body, once a week), that resulted in complete remission of the skin lesion (Case 1) and partial remission of cervical lymphnode (Case 2).In our cases, docetaxel was administrated in multi-therapy resistant patient, and it was effective. We suggest that docetaxel would be helpful for angiosarcoma of the scalp that resisted for the other therapy.[Skin Cancer (Japan) 2001; 16: 99-103]

Report of two cases of angiosarcoma of the scalp treated with Docetaxel.